Exercise of Options and Warrants
April 03 2009 - 9:37AM
UK Regulatory
TIDMTED
RNS Number : 1236Q
Tepnel Life Sciences PLC
03 April 2009
Tepnel Life Sciences plc ('Tepnel' or 'the Company')
Exercise of Options and Warrants
Manchester, UK, 3 April 2009: Tepnel Life Sciences PLC (AIM: TED), the
international Molecular Diagnostics and Research Products & Services group,
today announces that the Board of Directors approved the issue of 81,311,423 new
Ordinary Shares of 1 pence each in connection with the exercise of warrants and
options as detailed below:
+--------------------+----------------+
| Warrants |
+-------------------------------------+
| Exercise Price | Number |
| (pence) | |
+--------------------+----------------+
| 6.98 | 47,626,000 |
+--------------------+----------------+
| 8.05 | 2,484,145 |
+--------------------+----------------+
+--------------------+----------------+
| Options |
+-------------------------------------+
| Exercise Price | Number |
| (pence) | |
+--------------------+----------------+
| 22 | 130,000 |
+--------------------+----------------+
| 6.125 | 3,786,278 |
+--------------------+----------------+
| 5.32 | 2,000,000 |
+--------------------+----------------+
| Nil | 25,285,000 |
+--------------------+----------------+
Due to the timing of the exercise of Options and Warrants and the ongoing Scheme
of Arrangement it will not be possible to apply for the application of the
81,311,423 new Ordinary Shares to be admitted to AIM. The number of shares in
issue is as detailed in the Rule 2:10 announcement released today.
-End-
For further information:
Tepnel Life Sciences plc
Ben Matzilevich, Chief Executive Officer
Michael Slater, Group Finance Director
Carol Smith, Group Marketing Communications Manager
Tel: 0161 946 2200
Capital MS&L
Mary Clark or Catie Corcoran
Tel: +44 20 7307 5330
Seymour Pierce Limited
Mark Percy
Tom Sheldon
Christopher Wren
Tel: +44 20 7107 8000
About Tepnel Life Sciences plc
Tepnel Life Sciences (AIM:TED) is a UK-based international life sciences
products and services Group with two divisions, Molecular Diagnostics and
Research Products & Services. The Company has laboratories, manufacturing and
operations in the USA, UK and France with over 200 employees. Tepnel provides
test kits, reagents and services to two highly synergistic markets, these being
Molecular Diagnostics and Biomedical Research. The Company's strategy has been
to identify high growth niche opportunities within these multi-billion pound
markets. Tepnel focuses on these niche operations with internally developed
products, patents, expertise and know-how as well as strategic acquisitions, to
develop a leadership position within these defined market segments. For more
information please visit www.tepnel.com.
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCCKNKNNBKDQQK
Ted Baker (LSE:TED)
Historical Stock Chart
From Jun 2024 to Jul 2024
Ted Baker (LSE:TED)
Historical Stock Chart
From Jul 2023 to Jul 2024